The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.
 
Min Yuen Teo
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Pharmacyclics (Inst)
 
Neha Ratna
No Relationships to Disclose
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Danielle Elise Zimmerman
No Relationships to Disclose
 
Deaglan Joseph McHugh
Consulting or Advisory Role - Progenics
 
Andrew Leonard Laccetti
Consulting or Advisory Role - Bayer
 
Han Xiao
No Relationships to Disclose
 
Chung-Han Lee
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai
 
David Henry Aggen
Consulting or Advisory Role - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Kite, a Gilead company; Kronos Bio (I); Neogene Therapeutics (I); Urogen pharma (I); Vaxigene Therapeutics; Vaxigene Therapeutics; Vida Ventures (I)
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Immunai; Merck
Research Funding - AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
 
Gopa Iyer
Consulting or Advisory Role - Bayer; Janssen; Mirati Therapeutics
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - AstraZeneca; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Adicet Bio; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)